Actively Recruiting

Phase 1
Age: 21Years - 99Years
All Genders
NCT05687747

Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma

Led by National University Hospital, Singapore · Updated on 2025-04-04

100

Participants Needed

1

Research Sites

128 weeks

Total Duration

On this page

Sponsors

N

National University Hospital, Singapore

Lead Sponsor

N

National University of Singapore

Collaborating Sponsor

AI-Summary

What this Trial Is About

Single centre prospective evaluation of 68Gallium(Ga68)-FAPI-46 PET/MRI in patients diagnosed with Hepatocellular Carcinoma (HCC). 68Gallium-FAPI-46 PET/MRI and standard contrasted multiphasic MRI imaging will be acquired in patients with radiological or histological diagnosis of HCC. The PET scan results will be compared to standard imaging to evaluate its role in lesion detection, characterisation and staging in patients with HCC.

CONDITIONS

Official Title

Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma

Who Can Participate

Age: 21Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 21-99 years
  • Diagnosis of Hepatocellular Carcinoma based on histological assessment or radiological criteria per American Association for the Study of Liver Diseases guidelines
  • No prior locoregional therapy for Hepatocellular Carcinoma
  • Creatinine clearance greater than 30 ml/min based on Cockcroft Gault formula
  • Able to provide informed signed consent
Not Eligible

You will not qualify if you...

  • Allergy to 68Gallium-FAPI contrast agents
  • Contraindication to MRI, including MRI incompatible metallic implants, cardiac pacemaker, or claustrophobia
  • Weight greater than 150 kg
  • Known active malignancy other than Hepatocellular Carcinoma
  • Hepatic surgery within the last 30 days
  • Active inflammatory conditions affecting FAPI imaging, such as active infection, IgG4-related disease, or inflammatory bowel disease
  • Pregnancy; women of childbearing age must have a negative urine pregnancy test

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Robert John Walsh

Singapore, Singapore, 119074

Actively Recruiting

Loading map...

Research Team

R

Robert Walsh

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma | DecenTrialz